| Christine C Nelson, MD | |
|
1000 Wall Street, Ann Arbor, MI 48105-1912 | |
| (734) 764-4190 | |
| Not Available |
| Full Name | Christine C Nelson |
|---|---|
| Gender | Female |
| Speciality | Ophthalmology |
| Experience | 45 Years |
| Location | 1000 Wall Street, Ann Arbor, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578571261 | NPI | - | NPPES |
| 1666609 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 4301049161 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| University Of Michigan Health System | Ann arbor, MI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regents Of The University Of Michigan | 3779496856 | 2953 |
News Archive
Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.
Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.
•A new study published in the journal Nature Cell Biology has discovered how normal cells in tumors can fuel tumor growth.
Danaher Corporation announced today that GAAP net earnings for the quarter ended October 1, 2010 were $646.4 million, or $0.95 per diluted share, which includes a $0.34 gain related to the formation of the Apex Tool Group joint venture, and represents a 79% increase as compared to GAAP net earnings per diluted share of $0.53 for the third quarter 2009.
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.
› Verified 7 days ago
| Entity Name | Regents Of The University Of Michigan |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1568495299 PECOS PAC ID: 3779496856 Enrollment ID: O20031118000092 |
News Archive
Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.
Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.
•A new study published in the journal Nature Cell Biology has discovered how normal cells in tumors can fuel tumor growth.
Danaher Corporation announced today that GAAP net earnings for the quarter ended October 1, 2010 were $646.4 million, or $0.95 per diluted share, which includes a $0.34 gain related to the formation of the Apex Tool Group joint venture, and represents a 79% increase as compared to GAAP net earnings per diluted share of $0.53 for the third quarter 2009.
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christine C Nelson, MD 3621 S State St, 700 Kms Place, Ann Arbor, MI 48108 Ph: (734) 936-2047 | Christine C Nelson, MD 1000 Wall Street, Ann Arbor, MI 48105-1912 Ph: (734) 764-4190 |
News Archive
Two signaling pathways essential to normal human development - the Wnt/Wingless (Wnt) and epidermal growth factor receptor (EGFR) pathways - interact in ways that can promote tumor cell invasion and metastasis, researchers from The University of Texas M. D. Anderson Cancer Center report in the Nov. 25 issue of Molecular Cell.
Adamas Pharmaceuticals, Inc. presented positive results today from the Phase 2/3 EASED clinical trial of ADS-5102 at the World Parkinson's Congress. ADS-5102 is Adamas' proprietary long-acting capsule formulation of amantadine HCl in development for the treatment of levodopa-induced dyskinesia in Parkinson's disease patients.
•A new study published in the journal Nature Cell Biology has discovered how normal cells in tumors can fuel tumor growth.
Danaher Corporation announced today that GAAP net earnings for the quarter ended October 1, 2010 were $646.4 million, or $0.95 per diluted share, which includes a $0.34 gain related to the formation of the Apex Tool Group joint venture, and represents a 79% increase as compared to GAAP net earnings per diluted share of $0.53 for the third quarter 2009.
VistaGen Therapeutics, Inc., a stem cell technology company focused on drug discovery and development, today announced the successful completion of its initial Phase 1 safety study of AV-101, the Company's novel orally available prodrug candidate for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S.
› Verified 7 days ago
Said M Issa, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 2900 Golfside Dr, Suite 2, Ann Arbor, MI 48108 Phone: 313-724-2733 Fax: 313-724-2456 | |
Jill Elizabeth Bixler, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Paul P Lee, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Monte Anthony Delmonte, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Denise Ann-marie John, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall Street, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Brittany A Simmons, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-764-4190 | |
Alexander Valentine, MD Ophthalmology Medicare: Medicare Enrolled Practice Location: 1000 Wall St, Ann Arbor, MI 48105 Phone: 734-763-8122 |